Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 54 | 3,991 | 28% |
| 2020 | 48 | 3,508 | 30% |
| 2021 | 52 | 4,164 | 32% |
| 2022 | 56 | 4,203 | 35% |
| 2023 | 56 | 4,010 | 38% |
| 2024 | 60 | 4,610 | 39% |
| 2025 from claims | – | 5,136 4,713–5,434 | 40% |
| 2026 forecast | – | 5,450 4,795–6,290 | 39% |
| 2027 forecast | – | 5,701 4,874–6,794 | 40% |
| 2028 forecast | – | 5,964 4,976–7,303 | 40% |
| 2029 forecast | – | 6,238 5,095–7,823 | 40% |
| 2030 forecast | – | 6,525 5,228–8,362 | 40% |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 51% of the cases CMS names in Massachusetts; 25 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 37% inpatient hospital, 63% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 101 | 6,049−4.1%/yr | −4.1%/yr | 3.4 | 1% | 6,420 in 2030+1%/yr |
| Pennsylvania | 86 | 5,501−2.6%/yr | −2.6%/yr | 4.1 | 1% | 6,190 in 2030+2%/yr |
| New Jersey | 46 | 3,131−1%/yr | −1%/yr | 3.0 | 3% | 3,440 in 2030+1.6%/yr |
| Connecticut | 21 | 1,255−2.8%/yr | −2.8%/yr | 3.9 | 0% | 1,450 in 2030+2.4%/yr |
| New Hampshire | 10 | 688+1.5%/yr | +1.5%/yr | 3.1 | 0% | 920 in 2030+5%/yr |
| Maine | 6 | 387−3.6%/yr | −3.6%/yr | 2.5 | 0% | 440 in 2030+2.2%/yr |
| Rhode Island | 5 | 246−4.6%/yr | −4.6%/yr | 2.8 | 0% | 240 in 2030−0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 512 | 113,822−0.9%/yr | −0.9%/yr | 123.61.0× | 22% | 128,100 in 2030+2%/yr |
| Bronchoscopy & lung nodule | 48 | 3,057+5.5%/yr | +5.5%/yr | 3.31.1× | 0% | 4,980 in 2030+8.5%/yr |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Olympus leads with 44% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 16 companies reported engagement with Massachusetts’s surgeons worth $156K in consulting, speaking, meals and travel tied to these products, about $2,597 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.